(Q38268914)

1 September 2017

1 reference

title

What the guidelines do not say: statin non-benefit groups (English)

1 reference

1 September 2017

Pamela B Morris

1

1 reference

1 September 2017

Kellie McLain

series ordinal

2

1 reference

1 September 2017

publication date

1 January 2015

1 reference

Current Atherosclerosis Reports

1 September 2017

published in

1 reference

1 September 2017

volume

17

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

468

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-014-0468-3

1 September 2017

exact match

0 references

cites work

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Application of new cholesterol guidelines to a population-based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Association between LDL-C and risk of myocardial infarction in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Premature cardiovascular disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Risk of incident diabetes among patients treated with statins: population based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statin therapy and risks for death and hospitalization in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statins and mortality among elderly patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Age and gender bias in statin trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Safety and efficacy of statins in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0468-3

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

21 January 2018

1 reference

12 December 2020

Clinical epidemiology of cardiovascular disease in chronic renal disease

1 reference

12 December 2020

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

12 December 2020

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

1 reference

12 December 2020

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

12 December 2020

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

12 December 2020

Statins for the primary prevention of cardiovascular disease

1 reference

12 December 2020

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

10.1007/S11883-014-0468-3

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1027564508

0 references

1 reference